Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRAI sequential tocilizumab followed by rituximab study in DMARD-inadequate responder rheumatoid arthritis
2010-022049-88Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab and rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: DAS28 remission at week 16. Started Nov 2010; status: completed.
02
Drugs
tocilizumabrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022049-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022049-88.